Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
TVTX related parties submitted a Form 144 notice to sell common stock. The filing lists proposed sales tied to a Performance Restricted Stock Unit vesting on 04/13/2026 and multiple past sale entries: 9 shares on 04/14/2026, 65 shares on 04/13/2026, 1,745 shares on 02/04/2026, and 7,242 shares on 02/03/2026. The transactions are reported as compensation-related and list an issuer broker address for Morgan Stanley Smith Barney.
Molecular Templates, Inc. (TVTX) reported proposed sales of common stock by an affiliate under a Form 144. The filing lists three proposed dispositions: 65 shares for $1,875.25 (04/13/2026), 1,745 shares for $56,165.62 (02/04/2026), and 7,242 shares for $232,616.03 (02/03/2026). The securities are described as Restricted Stock and the broker is Morgan Stanley Smith Barney LLC.
TVTX submitted a Form 144 notice proposing the sale of 37,500 shares of Common Stock related to a stock option exercise, with the proposed sale dated 04/14/2026 and cash proceeds indicated. The filing also lists multiple recent open-market dispositions by Elizabeth Reed, each showing trade dates, share counts, and gross proceeds.
TVTX submitted a Form 144 notice reporting the proposed sale of 32,750 common shares via a stock option exercise on 04/14/2026, with cash as the payment method. The filing also records a prior sale of 10,000 common shares by Roy Baynes on 04/06/2026 for $330,000.
Sandra Calvin filed a Form 144 reporting proposed resales of Common Stock and recent dispositions. The filing lists 1,263 restricted shares dated 01/21/2025, 5,464 restricted shares dated 01/31/2025, and 15,250 shares from a stock option exercise dated 04/14/2026. It also reports 4,333 shares sold on 02/03/2026 for $139,177.16. A broker-dealer listed is Morgan Stanley Smith Barney LLC.
Travere Therapeutics reported that the FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults and children 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is now the first and only FDA‑approved medicine specifically for FSGS, expanding its use beyond IgA nephropathy into a second rare kidney disease.
The company estimates a U.S. addressable population of more than 30,000 FSGS patients without nephrotic syndrome. In the Phase 3 DUPLEX study, FILSPARI cut proteinuria by 46% from baseline to Week 108 in the overall population versus 30% with irbesartan, and by 48% versus 27% in patients without nephrotic syndrome, with statistically significant results. FILSPARI also showed a modest eGFR benefit and was generally well tolerated with a safety profile comparable to irbesartan.
TeleVox Media, Inc. submitted a Form 144 notice regarding proposed sales of 65 shares of Common Stock tied to restricted stock unit vesting on 04/10/2026. The filing lists 92,241,550 shares outstanding as of 04/13/2026 and records prior sales by Christopher Cline of 1,745 shares and 7,242 shares in February 2026.
Travere Therapeutics director Roy D. Baynes exercised and sold shares in a planned transaction. On April 6, 2026, he exercised stock options for 10,000 shares of Common Stock at an exercise price of $26.52 per share and received 10,000 shares.
That same day, he completed an open-market sale of 10,000 Common Stock shares at $33.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025. Following these transactions, Baynes directly holds 37,500 Common Stock shares.